Letermovir: Phase II data

A double-blind, U.S. and German Phase II trial in 133 CMV-seropositive allogeneic HBPC transplant recipients showed that once-daily 120 and 240 mg oral letermovir each met the co-primary endpoint of reducing the incidence of CMV prophylaxis failure, defined as development of systemic detectable CMV replication (viral load >42 DNA copies/mL) or CMV end-organ disease, at day 84 vs. placebo (32.3% and 29.4%, respectively, vs. 63.6%; p=0.014 and p=0.007). High-dose letermovir also met the co-primary endpoint of reducing time to onset of CMV prophylaxis failure vs. placebo (p=0.02). Data for low-dose letermovir on the time to onset of CMV prophylaxis failure endpoint were not disclosed. ...